MRK•Merck said intismeran plus Keytruda reduced the risk of recurrence or death by 42% versus Keytruda alone; the brief also cited a 58% reduction and a 38% reduction in distant metastasis or death.
Merck said the combination significantly reduced the risk of recurrence or death compared with Keytruda alone. The brief cited reductions of 42% and 58% for recurrence or death, and a 38% reduction for distant metastasis or death. Merck said overall survival data were not yet mature, though it had observed a favorable trend, and reported no new safety signals.
